Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2018

View Archived Issues

Expression of semaphorins 4D and 3A is regulated by adenosine A2A receptor in bone homeostasis

Bio-Thera Solutions initiates phase I study of tocilizumab biosimilar BAT-1806

Foresee completes phase I study of ALDH2 activator FP-045

Ignoring mutation and targeting inflammation

Myelin restoration: hold the fat

Freezing-induced dominant conformation facilitates peptide ligation during IFN-epsilon synthesis

FGF21 gene transfer by adeno-associated viral vectors as therapy for obesity and insulin resistance

11Leu allele of TLR7 gene a protective factor of fibrosis progression in HIV/HCV coinfected patients

Influenza RNA-directed RNA polymerase inhibitors patented by Sunshine Lake Pharma

CV6 Therapeutics presents deoxyuridine nucleotidohydrolase inhibitors

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical identify A2A receptor antagonists

BRD4 inhibitors patented by Luoxin Biotechnology Shanghai, Shandong Luoxin Pharmacy Group

PKR targeting benefits spatial memory and brain lesions in AD model

New compound inhibits Wnt, activates p53, targets CRC

Tonix to stop HONOR study of Tonmya for PTSD due to inadequate separation from placebo at week 12

FDA approves Perseris once-monthly subcutaneous injection for schizophrenia

FDA issues complete response letter for Insys' buprenorphine sublingual spray

Promising phase I results with KY-1005 pave way for phase II evaluation in atopic dermatitis

European Commission approves adalimumab biosimilar Hyrimoz

CRISPR-Cas9 DeltaFosB knockdown provides model of overeating

Researchers find SCRN1 presence in early neurofibrillary tangles in AD pathology

WP-1066 begins first-in-human study in recurrent malignant glioma and brain metastasis from melanoma

Daiichi Sankyo and Glycotope sign licensing agreement for gatipotuzumab-based ADC

LIDDS reports preclinical findings with NanoZolid-formulated STING agonist

Invectys begins phase II trial of INVAC-1 for high-risk CLL